The experimental drug reduced flare-ups for patients with chronic obstructive pulmonary disease, Astra said Friday.
GD analyst, Vinie Varkey notes that tozorakimab could capture a "significant patient share" as an add-on therapy in COPD.
March 27 () - AstraZeneca said on Friday its experimental respiratory treatment tozorakimab showed a meaningful reduction in ...
A key question for ESO-T01 and other in vivo candidates will be the durability of their cancer eradication. While the ...
AstraZeneca PLC (NASDAQ:AZN) has delivered a solid trailing 12 months, with shares up 31.43% over the past year. Year-to-date ...
Tozorakimab met the primary goal in two late-stage clinical trials, reducing the rate at which patients’ symptoms worsened, ...
Whatever the reasons, AstraZeneca has emerged as the first IL-33 player to show consistent efficacy. Sanofi and Regeneron ...
Friday's positive trial results for tozorakimab mark a significant inflexion point for AstraZeneca PLC (LSE:AZN, NASDAQ:AZN), ...
AstraZeneca jumps 4% after COPD drug wins Phase 3 trials. Tozorakimab success seen as rare win in tough COPD drug race.
French biotech Abivax has been the subject of intense takeover speculation for months. But a spokesperson denied a report by La Lettre that AstraZeneca was ...
The company is establishing commercial production capabilities to fuel plans to launch autologous CAR T cell therapies in ...
By Pushkala Aripaka, Nithyashree R B and Maggie Fick March 27 (Reuters) - AstraZeneca's experimental drug tozorakimab reduced ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results